Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 85

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 85
---
 to the Credit Line.The Company has the right to repay any variable rate advance under the Credit Line at any time, in whole or in part, without penalty. The Company may repay any fixed rate advance in whole, but may not repay any fixed rate advance in part. In its discretion and without cause, UBS has the right at any time to demand full or partial payment of amounts borrowed pursuant to the Credit Line and terminate the Credit Line.

As of March 31, 2025 and December 31, 2024, there was no outstanding debt under the Credit Line. 

14

9.    Share-Based Payments

Share-based compensation expense is as follows (dollars in thousands):Three Months EndedMarch 31,20252024(unaudited)Research and development$1,412 $1,365 Selling, general and administrative6,656 4,532 Total$8,068 $5,897 Stock Option The following table summarizes stock option activities:Number ofOptionsWeighted AverageExercise PriceWeightedAverageRemainingContractualTerm (in years)Outstanding, December 31, 20246,719,073 $30.44 5.9Granted 1,057,275 $33.86 Exercised (95,182)$21.46 Forfeited (31,924)$31.72 Outstanding, March 31, 2025 (unaudited)7,649,242 $31.01 6.3As of March 31, 2025 (unaudited):Vested and expected to vest7,649,242 $31.01 6.3Exercisable 4,893,002 $30.13 4.8As of December 31, 2024:Vested and expected to vest6,719,073 $30.44 5.9Exercisable4,137,283 $29.54 4.4Restricted Stock UnitsThe following table summarizes restricted stock unit (RSU) activities:Number ofRSUsWeighted AverageGrant Date Fair Value per ShareNonvested, December 31, 2024378,165 $32.48 Granted169,775 $33.52 Vested(136,673)$32.33 Forfeited(3,400)$32.17 Nonvested, March 31, 2025 (unaudited)407,